financetom
Business
financetom
/
Business
/
What's Going On With Oklo Shares Today?
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
What's Going On With Oklo Shares Today?
May 26, 2025 1:32 PM

Oklo Inc. ( OKLO ) shares are trading higher Friday as part of a broad rally in uranium and nuclear-related stocks.

What To Know: The move comes after reports indicating President Donald Trump is expected to sign executive orders aimed at revitalizing the U.S. nuclear energy industry.

Trump plans to invoke the Defense Production Act to declare a national emergency over the United States' dependence on foreign uranium. The executive actions are expected to direct federal agencies to fast-track nuclear energy projects in a bid to strengthen domestic supply chains and energy security.

The renewed focus on nuclear power comes amid growing electricity demand from artificial intelligence infrastructure and data centers, which require substantial and reliable energy sources. Investors are betting that nuclear power will play a bigger role in meeting that demand, driving up both uranium prices and the value of companies involved in nuclear development.

Oklo ( OKLO ), a developer of advanced fission reactors, was among the biggest gainers alongside peers such as Nano Nuclear Energy, Uranium Energy Corp and Energy Fuels. The entire uranium sector benefited from speculation that increased government support could accelerate deployment and commercialization of next-generation nuclear technologies.

The Global X Uranium ETF (URA), which tracks a basket of uranium producers and component manufacturers, also gained significantly, highlighting widespread investor optimism about the sector's outlook under a pro-nuclear policy shift.

OKLO Price Action: Oklo ( OKLO ) shares were up 24.9% at $49.60 at the time of writing, according to Benzinga Pro.

Read Next:

Trump Tariff Threat Hits Europe: Stocks Sink As 50% Duties Loom

Image Via Shutterstock.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Curbline Properties Q3 Operating FFO, Revenue Rise; Annual Operating FFO Guidance Upgraded
Curbline Properties Q3 Operating FFO, Revenue Rise; Annual Operating FFO Guidance Upgraded
Oct 28, 2025
06:44 AM EDT, 10/28/2025 (MT Newswires) -- Curbline Properties ( CURB ) reported Q3 operating funds from operations Tuesday of $0.28 per diluted share, up from $0.19 a year earlier. Four analysts polled by FactSet expected $0.27. Revenue for the quarter ended Sept. 30 was $48.6 million, up from $29.8 million a year earlier. Analysts surveyed by FactSet expected $42.9...
Zebra Technologies Q3 sales edge past estimates on lower-than-expected tariff impact
Zebra Technologies Q3 sales edge past estimates on lower-than-expected tariff impact
Oct 28, 2025
Overview * Zebra Q3 net sales rise 5.2% yr/yr, beating analyst expectations * Adjusted EPS for Q3 beats analyst expectations, reflecting strong operational performance * Company plans $500 mln share repurchase over next 12 months Outlook * Company expects Q4 sales growth between 8% and 11% * Adjusted EBITDA margin for Q4 expected to be around 22% * Non-GAAP EPS...
Cruise operator Royal Caribbean beats Q3 adjusted EPS expectations, lifts FY forecast
Cruise operator Royal Caribbean beats Q3 adjusted EPS expectations, lifts FY forecast
Oct 28, 2025
Overview * Royal Caribbean Q3 adjusted EPS beats analyst expectations, driven by strong demand and lower costs * Company raises full-year 2025 adjusted EPS guidance to $15.58-$15.63, up 32% yr/yr Outlook * Royal Caribbean raises 2025 Adjusted EPS guidance to $15.58-$15.63 * Company says 2026 bookings have come in at rates well above the prior year * Company expects 2026...
Regeneron Pharma's Q3 profit beats on Dupixent strength
Regeneron Pharma's Q3 profit beats on Dupixent strength
Oct 28, 2025
Overview * Regeneron Q3 2025 revenue grows 1% to $3.75 bln, beating analyst expectations * Adjusted EPS for Q3 2025 beats consensus, driven by strong product sales * Company reports strong sales growth for Dupixent and EYLEA HD Outlook * Regeneron updates 2025 R&D expense guidance to $5.68-$5.75 bln * Company revises 2025 SG&A expense guidance to $2.775-$2.845 bln *...
Copyright 2023-2026 - www.financetom.com All Rights Reserved